Tzield Now Approved for Newly Diagnosed Type 1 Diabetes in Young People

Tzield (teplizumab) is a disease-modifying therapy that helps preserve the insulin-producing cells in the pancreas. In type 1 diabetes, the immune system mistakenly attacks these beta cells, gradually destroying them. Tzield works by targeting immune cells involved in this attack, helping to slow or delay the destruction of beta cells.

The drug is given as an intravenous infusion over two separate 12-day courses. It was first approved by the FDA in 2022 to delay the onset of stage 3 type 1 diabetes in people aged 8 and older who had stage 2 diabetes—an early stage with no obvious symptoms. Now it has been approved for use in stage 3, meaning people recently diagnosed with clinical type 1 diabetes can access it.

Tzield is approved for children and adolescents aged 8-17 with stage 3 type 1 diabetes who were diagnosed within the last 8 weeks. This narrow window means treatment should begin soon after diagnosis. A prescription is required, and the therapy will be administered in clinical settings.

The FDA granted approval through its accelerated approval pathway, which means the agency determined the drug is safe and reasonably likely to provide clinical benefit based on available evidence. Additional clinical studies are ongoing to confirm these benefits over time.

The PROTECT clinical trial demonstrated that Tzield could safely and effectively preserve beta cell function in newly diagnosed children and adolescents. Patients treated with Tzield had significantly higher levels of C-peptide—a marker of insulin production—compared to those receiving placebo at 78 weeks.

In the trial, 94.9% of patients treated with Tzield maintained clinically meaningful beta cell function, compared to 79.2% of those receiving placebo. Real-world benefits included improved HbA1c levels (a measure of long-term blood sugar control), more time spent in target glucose range, less hypoglycemia, and reduced insulin requirements.

Tzield was generally well tolerated in clinical trials. The most common side effects included lymphopenia (low white blood cell count), rash, and headache. Most adverse events occurred during and after the first few weeks of treatment and resolved without intervention.

An integrated safety analysis of over 1,000 patients showed the side effect profile was consistent across multiple trials. As with any therapy, patients should discuss potential risks and benefits with their healthcare team.

Tzield's approval for stage 3 diabetes represents the first disease-modifying therapy available to people at or near the time of clinical diagnosis. Because preserving beta cell function is linked to better diabetes outcomes, this offers a new option for families facing a recent type 1 diabetes diagnosis.

It is important to note that Tzield delays disease progression—it does not cure type 1 diabetes. People who receive Tzield will still have type 1 diabetes and will need to continue managing their blood sugar with insulin and other diabetes care tools. Clinical trials are ongoing to gather more information about long-term effects.

Origin: breakthrought1d.org (News report). Evidence: News report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.